Crossmark

711 Updated overall survival from PERLA, a phase II randomized double-blind trial of dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous non-small cell lung cancer (NSCLC)

Crossref DOI link: https://doi.org/10.1136/jitc-2024-SITC2024.0711

Published Online: 2024-11-05

Published Print: 2024-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Peters, Solange

Lim, Sun Min

Ortega Granados, Ana L

Fuentes, Christian Sebastián

Russo, Giuseppe Lo

Schenker, Michael

Ahn, Jin Seok

Reck, Martin

Locke, Kenneth

Szijgyarto, Zsolt

Buss, Elena

Stjepanovic, Neda

Diaz-Padilla, Ivan

Marinis, Filippo de
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04581824 at ClinicalTrials.gov

Documents that mention this clinical trial

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
https://doi.org/10.1200/jco.2023.41.16_suppl.9099

711 Updated overall survival from PERLA, a phase II randomized double-blind trial of dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2024-sitc2024.0711
License Information

License valid from 2024-10-28

Document is current

Any future updates will be listed below